Retatrutide, an experimental weight loss medication currently in clinical trials, has generated significant attention in both medical and investment communities as new data emerges about its potential benefits and risks.

The drug, which has not yet received FDA approval, is being studied as a potential treatment that could surpass existing weight loss medications like Ozempic in effectiveness. Clinical trial data suggests the medication may offer benefits beyond weight reduction, including improvements in blood sugar control and reductions in cardiovascular risk factors.

Recent study results indicate that patients using retatrutide experienced substantial weight loss alongside other health improvements. The research showed the treatment reduced knee osteoarthritis pain by approximately 70 percent and appeared to help with conditions including sleep apnea.

Despite lacking FDA approval, a CBS News investigation revealed that some healthcare providers are already prescribing retatrutide to patients. This practice raises concerns among medical professionals about the potential risks of using an unapproved medication outside of controlled clinical trial settings.

The drug's manufacturer has experienced significant stock price volatility, with shares declining substantially following the release of new safety data. The market reaction reflects investor concerns about potential side effects and regulatory hurdles that could affect the medication's path to approval.

Retatrutide remains in clinical trials as researchers continue to evaluate its safety profile and effectiveness compared to existing treatments. The FDA has not indicated a timeline for potential approval of the medication.